Literature DB >> 27693018

A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.

Mariana Costa Duarte1, Daniela Pagliara Lage2, Vívian Tamietti Martins2, Lourena Emanuele Costa2, Ana Maria Ravena Severino Carvalho3, Fernanda Ludolf2, Thaís Teodoro de Oliveira Santos2, Danniele Luciana Vale3, Bruno Mendes Roatt3, Daniel Menezes-Souza1, Ana Paula Fernandes4, Carlos Alberto Pereira Tavares5, Eduardo Antonio Ferraz Coelho6.   

Abstract

In the present study, two proteins cloned from Leishmania braziliensis species, a hypothetical protein (LbHyp) and the eukaryotic initiation factor 5a (EiF5a), were evaluated to protect BALB/c mice against L. amazonensis infection. The animals were immunized with the antigens, either separately or in combination, using saponin as an immune adjuvant in both cases. Spleen cells from vaccinated and later infected mice produced significantly higher levels of protein and parasite-specific IFN-γ, IL-12, and GM-CSF, in addition to low levels of IL-4 and IL-10. Evaluating the parasite load by means of a limiting dilution technique and quantitative Real-Time PCR, vaccinated animals presented significant reductions in the parasite load in both infected tissues and organs, as well as lower footpad swelling, when compared to the control (saline and saponin) groups. The best results regarding the protection of the animals were achieved when the combined vaccine was administered into the animals. Protection was associated with an IFN-γ production against parasite antigens, which was mediated by both CD4+ and CD8+ T cells and correlated with antileishmanial nitrite production. In conclusion, data from the present study show that this polyprotein vaccine, which combines two L. braziliensis proteins, can induce protection against L. amazonensis infection.
Copyright © 2016 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Cross-protection; Eukaryotic initiation factor 5a; Hypothetical proteins; Tegumentary leishmaniasis; Th1 immunity; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 27693018     DOI: 10.1016/j.imbio.2016.09.015

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  8 in total

1.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

2.  Development of an immunogen containing CD4+/CD8+ T-cell epitopes for the prophylaxis of tegumentary leishmaniasis.

Authors:  Isabela de Andrade Ferraz; Ana Maria Ravena Severino Carvalho; Rory Cristiane Fortes de Brito; Bruno Mendes Roatt; Vívian Tamietti Martins; Daniela Pagliara Lage; Luiza Dos Reis Cruz; Fernanda Alvarenga Cardoso Medeiros; Denise Utsch Gonçalves; Manoel Otávio da Costa Rocha; Eduardo Antonio Ferraz Coelho; Tiago Antônio de Oliveira Mendes; Mariana Costa Duarte; Daniel Menezes-Souza
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-27       Impact factor: 5.560

3.  Analysis of the Antigenic and Prophylactic Properties of the Leishmania Translation Initiation Factors eIF2 and eIF2B in Natural and Experimental Leishmaniasis.

Authors:  Esther Garde; Laura Ramírez; Laura Corvo; José C Solana; M Elena Martín; Víctor M González; Carlos Gómez-Nieto; Aldina Barral; Manoel Barral-Netto; José M Requena; Salvador Iborra; Manuel Soto
Journal:  Front Cell Infect Microbiol       Date:  2018-04-05       Impact factor: 5.293

4.  The F1F3 Recombinant Chimera of Leishmania donovani-Nucleoside Hydrolase (NH36) and Its Epitopes Induce Cross-Protection Against Leishmania (V.) braziliensis Infection in Mice.

Authors:  Marcus Vinícius Alves-Silva; Dirlei Nico; Paula Melo de Luca; Clarisa B Palatnik de-Sousa
Journal:  Front Immunol       Date:  2019-04-09       Impact factor: 7.561

5.  Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice.

Authors:  Abel Martínez-Rodrigo; Daniel S Dias; Patrícia A F Ribeiro; Bruno M Roatt; Alicia Mas; Javier Carrión; Eduardo A F Coelho; Gustavo Domínguez-Bernal
Journal:  Vaccines (Basel)       Date:  2019-11-14

6.  Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis.

Authors:  Alireza Lari; Niloofar Lari; Atefeh Biabangard
Journal:  Int J Pept Res Ther       Date:  2021-12-16       Impact factor: 1.931

7.  An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.

Authors:  Md Anik Ashfaq Khan; Jenifar Quaiyum Ami; Khaledul Faisal; Rajashree Chowdhury; Prakash Ghosh; Faria Hossain; Ahmed Abd El Wahed; Dinesh Mondal
Journal:  Parasit Vectors       Date:  2020-04-15       Impact factor: 3.876

Review 8.  The eukaryotic initiation factor 5A (eIF5A1), the molecule, mechanisms and recent insights into the pathophysiological roles.

Authors:  Michel Tauc; Marc Cougnon; Romain Carcy; Nicolas Melis; Thierry Hauet; Luc Pellerin; Nicolas Blondeau; Didier F Pisani
Journal:  Cell Biosci       Date:  2021-12-24       Impact factor: 7.133

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.